A detailed history of Fairman Group, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Fairman Group, LLC holds 6 shares of BIIB stock, worth $878. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6
Previous 6 -0.0%
Holding current value
$878
Previous $1.39 Million 16.39%
% of portfolio
0.0%
Previous 0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Mar 26, 2024

BUY
$222.59 - $267.94 $1,335 - $1,607
6 New
6 $1.55 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.1B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Fairman Group, LLC Portfolio

Follow Fairman Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fairman Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fairman Group, LLC with notifications on news.